Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy - Ryan, C J; Smith, M R; Fong, L (J Clin Oncol, 2010)